Shares of Third Harmonic Bio, Inc. (THRD) are up over 40% at $5.09 today, following the company's plans to liquidate and dissolve the company, returning capital to shareholders.
The company revealed that it will seek stockholder approval for the dissolution at its Annual Meeting of Stockholders scheduled for June 5, 2025. If the proposal is approved, Third Harmonic Bio plans to file a Certificate of Dissolution with the Secretary of State of Delaware during the third quarter of 2025.
As part of the dissolution process, the company anticipates distributing between approximately $246.6 million and $259.8 million to stockholders, equating to $5.13 to $5.42 per share of common stock. The initial distribution, expected to occur shortly after the filing of the Certificate of Dissolution, is estimated to be in the range of $246.6 million to $255.4 million, or approximately $5.13 and $5.33 per share of common stock.
The company's lead drug candidate is THB335, a potent and highly selective oral small molecule inhibitor of KIT, with initial development efforts focused on chronic spontaneous urticaria. All Phase 2 readiness activities for THB335 are expected to be completed by mid-year 2025.
Commenting on the developments, Natalie Holles, Chief Executive Officer of Third Harmonic Bio, said, "Our management team and board of directors together have completed an efficient review of our strategic alternatives for maximizing the value of our assets and have determined that returning cash to shareholders and selling our assets, including THB335, is the best path forward."
In the last 1 year, THRD has traded in a range of $3.18 to $16.94.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.